Idec submits Zevalin BLA

IDPH submitted a BLA to the FDA for its Zevalin ibritumomab tiuxetan ( IDEC-Y2B8) to treat low-grade or follicular, relapsed or refractory, CD20-positive, B cell non-Hodgkin's lymphoma (NHL), and foll...